WHO Sounds Concern Over Acute Scarcity of Obesity Jabs
Less than a tenth of patients eligible to benefit from obesity jabs such as Wegovy are able to get them, caution the WHO as it releases its initial recommendations on the therapies.
With over a billion individuals worldwide now classified as obese, it is advocating for increased and just availability to these injectable treatments.
According to estimates, more than two billion are projected to be obese by 2030 if no action is taken.
"Our latest guidelines recognises that obesity is a long-term condition that can be addressed with holistic and continuous support," said the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are key barriers to widespread access to the treatments that can aid individuals in losing considerable body mass, notes the body.
GLP-1 Therapy Scarcity
Even under the present most optimistic case, the manufacturing of such drugs would only suffice for approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice calls on countries and companies to increase access, through strategies including patent sharing.
The intellectual property rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
How Weight-Loss Jabs Work
These medications mimick a natural hormone to delay gastric emptying, suppress the appetite and enhance satiety so individuals consume fewer calories.
Individuals typically begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Studies indicates people may regain a significant portion after a year of halting the treatment, as their usual food cravings return.
To be above a healthy weight increases your likelihood for contracting diseases, such as type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity impacts individuals in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
